Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...
He is just the fifth person in the world to be part of the clinical trial ...
The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...
Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...
The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...
A cancer diagnosis can be one of the most frightening moments in a person’s life. One of the first questions many people ask is how long they will live. This is a very natural question, but the answer ...
Germline radiosensitivity biomarker for radiation-induced GU toxicity following radiation therapy in localized prostate cancer (GARUDA): Two-year outcomes of a phase II clinical trial.
Real-world treatment transitions and healthcare resource utilization in patients with metastatic castration-resistant prostate cancer in Colombia. This is an ASCO Meeting Abstract from the 2026 ASCO ...
(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Henk van der Poel discussing the optimal management of ...
State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...
Delays in treating a patient with an aggressive form of prostate cancer more than likely contributed to his disease advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results